| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/JAC/13.SUPPL_A.9 |
| P953 | full work available at URL | http://academic.oup.com/jac/article-pdf/13/suppl_A/9/6772582/13-suppl_A-9.pdf |
| P698 | PubMed publication ID | 6365884 |
| P2093 | author name string | G. Kahlmeter | |
| J. I. Dahlager | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| toxicity | Q274160 | ||
| P304 | page(s) | 9-22 | |
| P577 | publication date | 1984-01-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | |
| P478 | volume | 13 Suppl A |
| Q40748729 | A clinical review of ototoxicity |
| Q41831809 | A histological study of the effect of exogenous melatonin on gentamicin induced structural alterations of proximal tubules in rats |
| Q44100813 | A role for superoxide in gentamicin-mediated nephropathy in rats |
| Q41474199 | Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients |
| Q51781194 | Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. |
| Q48303892 | Adverse effects of a single dose of gentamicin in adults: a systematic review |
| Q41807021 | Aminoglycoside antibiotics alter the electrogenic transport properties of cultured human proximal tubule cells |
| Q50435277 | Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions |
| Q39648907 | Aminoglycoside nephrotoxicity |
| Q38181171 | Aminoglycoside toxicity in neonates: something to worry about? |
| Q40802929 | Aminoglycoside-induced Fanconi's syndrome |
| Q38676819 | Aminoglycoside-induced hearing loss in humans |
| Q37224123 | Aminoglycoside-induced vestibular injury: maintaining a sense of balance |
| Q33863403 | An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure |
| Q35746986 | An update on otolaryngology in critical care |
| Q37352354 | An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics |
| Q33604536 | Antibacterial-induced nephrotoxicity in the newborn |
| Q39524966 | Antibiotic selection and pharmacokinetics in the critically ill. |
| Q28386555 | Antibiotic treatment enhances the genome-wide mutation rate of target cells |
| Q33429288 | Antimicrobial therapy for pediatric patients |
| Q47356562 | Application of Materials as Medical Devices with Localized Drug Delivery Capabilities for Enhanced Wound Repair |
| Q50434466 | Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit |
| Q30461520 | Assessment of aminoglycoside-induced hearing impairment in hospitalized neonates by TEOAE. |
| Q34583543 | Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics |
| Q41049463 | Biotransformation and membrane transport in nephrotoxicity |
| Q30440719 | Bumetanide hyperpolarizes madin-darby canine kidney cells and enhances cellular gentamicin uptake by elevating cytosolic Ca(2+) thus facilitating intermediate conductance Ca(2+)--activated potassium channels |
| Q68864104 | Cefotetan and the lack of associated bleeding |
| Q55038177 | Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection |
| Q35571259 | Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia |
| Q52506078 | Chronokinetic study of netilmicin in man. |
| Q39598341 | Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services |
| Q73499961 | Collisionally activated dissociations of aminocyclitol-aminoglycoside antibiotics and their application in the identification of a new compound in tobramycin samples |
| Q35090305 | Community health workers can identify and manage possible infections in neonates and young infants: MINI--a model from Nepal |
| Q61577436 | Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis |
| Q35885240 | Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children |
| Q39238872 | Computer modelling antibiotic therapy costs. Impact of therapeutic range |
| Q50588847 | Cost effectiveness of three drugs for the treatment of S. aureus infections in Nigeria. |
| Q28361867 | Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis |
| Q37839231 | Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity |
| Q37328789 | Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis. |
| Q51580651 | Day-night treatment difference of tobramycin serum and intrarenal drug distribution and nephrotoxicity in rats: effects of fasting. |
| Q34468680 | Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retro |
| Q44126628 | Dietary composition alters gentamicin-induced nephrotoxicity in rats |
| Q43591246 | Differential toxicity expression of gentamicine in five-sixths nephrectomized rats assigned to three progressive stages of renal dysfunction--establishment of a new screening approach |
| Q39524684 | Drug-induced ototoxicity |
| Q38173853 | Drug-induced renal Fanconi syndrome |
| Q37213753 | Drug-induced renal toxicity. Help in recognizing offending agents |
| Q39557979 | Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy |
| Q59688603 | Easier monitoring of aminoglycoside therapy with once-daily dosing schedules |
| Q33976169 | Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration |
| Q36167408 | Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures |
| Q37905522 | Evaluation of methods to estimate glomerular filtration rate versus actual drug clearance in patients with chronic spinal cord injury |
| Q40246620 | Exogenous control of mammalian gene expression via modulation of translational termination |
| Q40594113 | Experimental, clinical and preventive aspects of ototoxicity |
| Q37237625 | Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries. |
| Q37400219 | Extract of Ferula foetida regel reverses gentamicin-induced nephrotoxicity in rats |
| Q33751758 | Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics |
| Q91769245 | Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial |
| Q34411596 | Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin |
| Q50433278 | Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. |
| Q35285645 | Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis |
| Q43580192 | Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs |
| Q36004047 | Induction and inhibition of pinocytosis by aminoglycoside antibiotics |
| Q83137944 | Interaction of gentamicin with phosphatidylserine/phosphatidylcholine mixtures in adsorption monolayers and thin liquid films: morphology and thermodynamic properties |
| Q72257273 | Intravenous administration of gentamicin once daily versus thrice daily in adults |
| Q47592843 | Is aminoglycoside-associated nephrotoxicity uncommon in the U.K? |
| Q39566914 | Kidney tissue repair after nephrotoxic injury: biochemical and morphological characterization |
| Q68364709 | Light and electron microscopic characterization of the proliferative response induced by tobramycin in rat kidney cortex |
| Q77482743 | Mass spectrometric studies on the fragmentation and structural characterization of aminoacyl derivatives of kanamycin A |
| Q36720602 | Molecular parameters involved in aminoglycoside nephrotoxicity |
| Q52618294 | Mutational biosynthesis of neomycin analogs by a mutant of neomycin-producing Streptomyces fradiae. |
| Q43916925 | Netilmicin effect on urinary retinol binding protein (RBP) and N-acetyl-beta-D-glucosaminidase (NAG) in preterm newborns with and without anoxia. |
| Q38739367 | Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. |
| Q45991071 | No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. |
| Q33982886 | Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. |
| Q24245588 | Once a day vs multiple doses a day regimen of gentamicin for treatment of suspected or proven sepsis in neonates |
| Q33569075 | Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects |
| Q46860894 | Once-daily dosing of aminoglycosides |
| Q24235032 | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates |
| Q24244642 | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates |
| Q36214025 | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. |
| Q41599948 | Osteocompatibility of biofilm inhibitors |
| Q39510044 | Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial |
| Q47377155 | Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? |
| Q40392377 | Parenteral aminoglycoside therapy. Selection, administration and monitoring |
| Q28325216 | Pentamidine-Associated Nephrotoxicity and Hyperkalemia in Patients with Aids |
| Q28328534 | Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection |
| Q44577237 | Pharmacokinetics and side-effects of gentamicin in healthy and pseudomonas aeruginosa infected sheep |
| Q40949882 | Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy |
| Q52861420 | Prediction of netilmicin disposition in neonates. |
| Q42831325 | Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. |
| Q33772759 | Prevention of adverse events in hospitalized patients using an antimicrobial review program |
| Q35834985 | Prevention of hepatorenal toxicity with Sonchus asper in gentamicin treated rats |
| Q33928638 | Principles of selection and use of antibacterial agents. In vitro activity and pharmacology |
| Q46496616 | Protective effect of edaravone against tobramycin-induced ototoxicity |
| Q28361543 | Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals |
| Q36366980 | Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital |
| Q35642347 | Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans |
| Q55405238 | Renal failure after placement of an articulating, antibiotic impregnated polymethylmethacrlyate hip spacer. |
| Q34472677 | Renal transport of antibiotics and nephrotoxicity: a review |
| Q40197955 | Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male |
| Q35538285 | Role of aminoglycoside antibiotics in the treatment of intra-abdominal infection |
| Q92497796 | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
| Q91075992 | Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers |
| Q36496656 | Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics |
| Q36134894 | Studying outcomes of intensive care unit survivors: the role of the cohort study |
| Q74025503 | Systemic absorption of gentamicin ear drops |
| Q40415348 | TRPV1 regulators mediate gentamicin penetration of cultured kidney cells. |
| Q43946107 | Testing the predictive ability of the "spinal cord injury equation" in estimating vancomycin clearance |
| Q38821699 | The amikacin research program: a stepwise approach to validate dosing regimens in neonates. |
| Q41138730 | The aminoglycosides |
| Q54399156 | The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. |
| Q39077216 | The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database |
| Q50553360 | The effect of taurine supplementation on the ototoxicity of neomycin in guinea pigs. |
| Q34917385 | The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. |
| Q35615484 | The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis |
| Q44541890 | The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre |
| Q54127154 | The utility of aminoglycosides in an era of emerging drug resistance. |
| Q39011332 | Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy |
| Q26829604 | Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis |
| Q38358856 | Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis |
| Q37800963 | Translational errors: from yeast to new therapeutic targets. |
| Q61858297 | Tubular proteinuria in pre-term and full-term infants |
| Q42470180 | Ultrastructural localization of megalin in the rat cochlear duct |
| Q30494217 | Uptake of fluorescent gentamicin by vertebrate sensory cells in vivo |
| Q41435517 | Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations |
| Q28379292 | Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy |
| Q39780630 | Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis |
| Q36459939 | Vestibulo-ocular reflex (VOR) in guinea pigs. Impairment induced by aminoglycoside antibiotics |
| Q36446781 | d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models |
Search more.